Human Cytokine-induced Killer Cells Specifically Infiltrated and Retarded the Growth of the Inoculated Human Cholangiocarcinoma Cells in SCID Mice
Overview
Authors
Affiliations
Cytokine-induced killer (CIK) cells were examined for safety and efficacy for cholangiocarcinoma treatment. Several conditions of human CIK cells were examined using ex vivo cytotoxic assay and SCID mice pre-inoculated with cholangiocarcinoma cells. We monitored the ex vivo cytotoxicity, tumor sizes and immunohistochemistry. Optimal tumor suppression was observed when CIK cells were pre-exposed to dendritic cells (DCs). Unexpectedly, pulsing of tumor RNA to DCs rendered the co-culturing CIK cells ineffective and raised the proportion of CD4(+)CD25(+) subset. The use of CD3(+)CD56(+) subset instead of the whole population of CIK cells for the co-culture with RNA-pulsed DCs restored the efficacy. Tumor-infiltrating human CD3(+) cells were observed from day 2 - 14. The CD3(+)CD56(+) cells are logical candidates for clinical trial while the DC-co-cultured CIK cells produced similar efficacy and more feasible for clinical application. The RNA pulsation of DCs up-regulated the regulatory subset of CIK cells and abrogated the anti-tumor efficacy.
Preclinical and clinical studies of immunotherapy for the treatment of cholangiocarcinoma.
Lu X, Green B, Xie C, Liu C, Chen X JHEP Rep. 2023; 5(7):100723.
PMID: 37229173 PMC: 10205436. DOI: 10.1016/j.jhepr.2023.100723.
Advances in molecular and cell therapy for immunotherapy of cholangiocarcinoma.
Zhao L, Shi A, Yang Y, Liu Z, Hu X, Shu L Front Oncol. 2023; 13:1140103.
PMID: 37064120 PMC: 10090456. DOI: 10.3389/fonc.2023.1140103.
Immune-Mediated Therapies for Liver Cancer.
Aravalli R, Steer C Genes (Basel). 2017; 8(2).
PMID: 28218682 PMC: 5333065. DOI: 10.3390/genes8020076.
Wongkajornsilp A, Numchaisermsuk N, Sa-Ngiamsuntorn K, Akarasereenont P, Wamanuttajinda V, Kasetsinsombat K BMC Complement Altern Med. 2016; 16(1):489.
PMID: 27899095 PMC: 5129228. DOI: 10.1186/s12906-016-1480-7.
Effect of cytokine-induced killer cells on immune function in patients with lung cancer.
Pan Y, Wu Y, Ji J, Cai H, Wang H, Jiang Y Oncol Lett. 2016; 11(4):2827-2834.
PMID: 27073559 PMC: 4812452. DOI: 10.3892/ol.2016.4284.